Recent News

• 03.31.2026 - Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
• 03.28.2026 - Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
• 03.18.2026 - Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
• 03.10.2026 - Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
• 03.05.2026 - Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
• 03.03.2026 - Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

Recent Filings

• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.02.2026 - 144 Report of proposed sale of securities
• 03.02.2026 - 144 Report of proposed sale of securities